AIMS: To evaluate the antimalarial agent quinine as a potential in vivo probe for hepatic cytochrome P450 (CYP) 3A4 activity. METHODS:Ten healthy adult volunteers received, by randomized crossover design, either a single oral dose of quinine sulphate (600 mg) alone, or quinine sulphate (600 mg) plus the CYP3A4 inhibitor troleandomycin (TAO; 500 mg every 8 h). Plasma and urine samples were collected before quinine administration, and up to 48 h thereafter, then analysed by h.p.l.c. for both quinine and its CYP3A4-generated metabolite, 3-hydroxyquinine. During both phases, the erythromycin breath test (ERMBT) was administered at specific times to assess hepatic CYP3A4 activity. RESULTS: Compared with control, TAO treatment significantly decreased the mean time-averaged ERMBT result by 77% (95% CI, 68, 85%), the mean apparent oral clearance of quinine (CL/F ) by 45% (95% CI, 39, 52%), and the mean apparent formation clearance of 3-hydroxyquinine (CL3-OH) by 81% (95% CI, 76, 87%). There was no correlation between the TAO-mediated percent decrease in the time-averaged ERMBT result and the percent decrease in CL/F or in CL3-OH. When TAO and control treatments were analysed separately, there were no significant correlations between the time-averaged ERMBT result and CL/F, CL3-OH, or single plasma quinine concentration at 12, 24, and 48 h. CONCLUSIONS: Quinine may be a useful probe to detect inhibition of liver CYP3A4 activity within an individual. Further studies are needed to determine whether it can provide a quantitative measure of CYP3A4 activity suitable for intersubject comparison.
RCT Entities:
AIMS: To evaluate the antimalarial agent quinine as a potential in vivo probe for hepatic cytochrome P450 (CYP) 3A4 activity. METHODS: Ten healthy adult volunteers received, by randomized crossover design, either a single oral dose of quinine sulphate (600 mg) alone, or quinine sulphate (600 mg) plus the CYP3A4 inhibitor troleandomycin (TAO; 500 mg every 8 h). Plasma and urine samples were collected before quinine administration, and up to 48 h thereafter, then analysed by h.p.l.c. for both quinine and its CYP3A4-generated metabolite, 3-hydroxyquinine. During both phases, the erythromycin breath test (ERMBT) was administered at specific times to assess hepatic CYP3A4 activity. RESULTS: Compared with control, TAO treatment significantly decreased the mean time-averaged ERMBT result by 77% (95% CI, 68, 85%), the mean apparent oral clearance of quinine (CL/F ) by 45% (95% CI, 39, 52%), and the mean apparent formation clearance of 3-hydroxyquinine (CL3-OH) by 81% (95% CI, 76, 87%). There was no correlation between the TAO-mediated percent decrease in the time-averaged ERMBT result and the percent decrease in CL/F or in CL3-OH. When TAO and control treatments were analysed separately, there were no significant correlations between the time-averaged ERMBT result and CL/F, CL3-OH, or single plasma quinine concentration at 12, 24, and 48 h. CONCLUSIONS:Quinine may be a useful probe to detect inhibition of liver CYP3A4 activity within an individual. Further studies are needed to determine whether it can provide a quantitative measure of CYP3A4 activity suitable for intersubject comparison.
Authors: T Aoyama; S Yamano; D J Waxman; D P Lapenson; U A Meyer; V Fischer; R Tyndale; T Inaba; W Kalow; H V Gelboin Journal: J Biol Chem Date: 1989-06-25 Impact factor: 5.157
Authors: C Ged; J M Rouillon; L Pichard; J Combalbert; N Bressot; P Bories; H Michel; P Beaune; P Maurel Journal: Br J Clin Pharmacol Date: 1989-10 Impact factor: 4.335
Authors: Harma Ellens; Shibing Deng; Joann Coleman; Joe Bentz; Mitchell E Taub; Isabelle Ragueneau-Majlessi; Sophie P Chung; Krisztina Herédi-Szabó; Sibylle Neuhoff; Johan Palm; Praveen Balimane; Lei Zhang; Masoud Jamei; Imad Hanna; Michael O'Connor; Dallas Bednarczyk; Malin Forsgard; Xiaoyan Chu; Christoph Funk; Ailan Guo; Kathleen M Hillgren; Libin Li; Anne Y Pak; Elke S Perloff; Ganesh Rajaraman; Laurent Salphati; Jan-Shiang Taur; Dietmar Weitz; Heleen M Wortelboer; Cindy Q Xia; Guangqing Xiao; Tetsuo Yamagata; Caroline A Lee Journal: Drug Metab Dispos Date: 2013-04-25 Impact factor: 3.922
Authors: S I Igbinoba; M A Akanmu; C O Onyeji; J O Soyinka; A R Owolabi; T I Nathaniel; S V Pullela; J M Cook Journal: J Clin Pharm Ther Date: 2015-07-14 Impact factor: 2.512
Authors: Sharon I Igbinoba; Cyprian O Onyeji; Moses A Akanmu; Julius O Soyinka; Srirama Sarma V V Pullela; James M Cook; Thomas I Nathaniel Journal: J Clin Pharmacol Date: 2014-12-22 Impact factor: 2.860